drugset / Trial / NCT04809389

A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

NCT04809389 ↗

Phase 1 Unknown 115 enrolled The University of Hong Kong
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To investigate the safety and immunogenicity profile of of a novel nasal spray investigational vaccine, which is a potential prophylactic vaccine for current pandemic disease COVID-19.

Timeline

Start
2021-03-29
Primary completion
2022-09
Completion
2022-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DelNS1-nCoV-RBD LAIV Vaccine 1e+07 unknown Intranasal
Subject DelNS1-nCoV-RBD LAIV Vaccine 5.01187e+07 unknown Intranasal

Indications